UNH | Weekly | Haru Insights

UnitedHealth Group (UNH) delivered a strong Q3 2026 earnings report, reporting adjusted EPS of $4.69—13.8% above estimates—and raised full-year 2026 guidance to at least $20.50 per share, signaling sustained operational strength despite systemic headwinds.
The company announced sweeping Medicare Advantage plan changes, including up to 30% prescription drug price hikes and benefit cuts in 2027, framed as “targeted adjustments” to restore margins amid escalating medical costs and government funding pressures.

UNH’s flawless Q3 2026 execution—powered by Optum’s AI-driven efficiency—proves its operational mastery, turning macroeconomic headwinds into profit expansion, and solidifying its status as a rare high-conviction growth engine in healthcare.
Record ETF inflows, including $18.5 million in net buying on October 15, 2026, and massive institutional purchases by JPMorgan’s JGLO and SPYV, reflect unshakable investor confidence in UNH’s resilience and long-term structural dominance.
The EPS beat and guidance raise confirm UNH’s superior margin management, demonstrating its ability to scale profitability even as industry-wide medical inflation pressures mount.
Optum’s AI optimization of claims processing and care coordination is not just a short-term win but a scalable competitive moat, setting a new benchmark in health tech integration across the industry.
Despite macro turbulence, UNH’s ability to raise full-year guidance while maintaining aggressive capital allocation underscores internal discipline and leadership precision.

UnitedHealth Group Incorporated (UNH)[Tv]